Glycine
In clinical developmentAlso known as Aminoacetic Acid, Aminoessigsäure, Aminoethanoic acid, Aminosyn 10%, Sulfite-Free+44 more
Aminoacetic Acid, Aminoessigsäure, Aminoethanoic acid, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Clinisol 15, Freamine III 10, Glicina, Gly, Glycine - amino acid, Glycine Oral, Glycocoll, Glykokoll, Hepatamine 8, Hepatasol, Plenamine, PremaSol, ProSol, ProcalAmine 3, Travasol 10, Travasol 10%, Trophamine, Trophamine 10 %, Trophamine 6 %, glycine urologic solution, Glycin, Glyzin, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25.
Recent clinical, regulatory, research and industry developments relating to this drug.
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity.
Glycine vs Placebo for the Schizophrenia Prodrome
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Long-term Impact and Intervention for Diarrhea in Brazil
Adjunctive Glycine for Obsessive Compulsive Disorder
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Long-term Impact and Intervention for Diarrhea in Brazil
Glycine vs Placebo for the Schizophrenia Prodrome
Recent completions
Trials that read out recently, adding to the completed evidence base.
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Glycine vs Placebo for the Schizophrenia Prodrome
Glycine Treatment of Prodromal Symptoms
Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST)
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes6
Journals, researchers & institutions
- The Journal of neuroscience : the official journal of the Society for Neuroscience2
- Cell1
- JAMA oncology1
- Abou-Alfa GK1
- Adeva J1
- Aguado-Fraile E1
- Akita T1
- Albuquerque EX1
- Alkondon M1
- Borad MJ1
- Bridgewater JA1
- Dana-Farber Cancer Institute1
- Department of Pharmacology and Experimental Therapeutics and Maryland Psychiatric Research Center1
- Hamamatsu University School of Medicine1
- Helen Diller Family Comprehensive Cancer Center1
- Hokkaido University1
- Hospital Universitario 12 de Octubre1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Glycine in the shared literature.
Studied across the same disease area as Glycine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials